EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant

Hikaru Kamo iD, Genko Oyama iD, Mai Shimizu, Haruka Takeshige-Amano, Takashi Ogawa iD, Wataru Sako, Noriko Nishikawa iD, Taku Hatano iD, Yuanzhe Li, Hiroyo Yoshino, Manabu Funayama iD, Masanobu Ito und 3 weitere

Movement Disorders Clinical Practice · 2026

DOI: 10.1002/mdc3.70411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Hikaru Kamo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation, Subthalamic Nucleus, Glucosylceramidase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant—the causative gene of Gaucher disease—associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)‐DBS.

Objectives

The aim of the study was to examine the relationship between outcomes after STN‐DBS and GBA1 variants in PD patients undergoing bilateral STN‐DBS.

Methods

Patients were retrospectively analyzed over 5 years, with clinical and genetic assessments, including GBA1 variant status performed at baseline and at 1‐, 3‐, and 5‐years post‐DBS. Longitudinal changes in motor, cognitive, and medication outcomes were evaluated using propensity score matching and linear mixed‐effects models.

Results

A total of 371 PD patients undergoing bilateral STN‐DBS were analyzed, including 54 GBA1 variant carriers and 253 noncarriers, after excluding other genetic variants. Propensity score matching yielded 2 groups with balanced baseline characteristics, with 50 patients each. Over time, no significant differences were observed in motor, cognitive, or neuropsychiatric assessments between groups. GBA1 carriers exhibited worsened medication OFF‐DBS off state motor symptoms at 5 years postoperatively, whereas cognitive function, assessed by the Mini‐Mental State Examination, remained stable in both groups. Levodopa‐equivalent daily dose (LEDD) significantly decreased in both groups. Linear mixed‐effects models showed progressive motor and cognitive decline and reduced medication use over 5 years, with no significant impact on GBA1 variant status.

Conclusions

Findings from Japan's largest genetic cohort suggest that GBA1 variants may not significantly affect postoperative motor or cognitive trajectories following STN‐DBS. Further validation through large‐scale multinational and multicenter studies is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDeep Brain StimulationSubthalamic NucleusGlucosylceramidaseCognitive DysfunctionHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeCognition

Stichwörter der Autor:innen

Parkinson's diseasecognitiondeep brain stimulationgeneticglucocerebrosidase

Substanzen

GlucosylceramidaseGBA protein, human

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Department of Neurology, Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.
  • Department of Neurology, Saitama Medical University, Saitama, Japan.
  • Department of Neurology, Juntendo Urayasu Hospital, Urayasu, Japan.
  • Department of Psychiatry, Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Department of Neurosurgery, Faculty of Medicine, Juntendo University, Tokyo, Japan.

ORCID-Profile: Hikaru Kamo, Genko Oyama, Takashi Ogawa, Noriko Nishikawa, Taku Hatano, Manabu Funayama, Atsushi Umemura

Zitieren

APA

Kamo, H., Oyama, G., Shimizu, M., Takeshige-Amano, H., Ogawa, T., Sako, W., Nishikawa, N., Hatano, T., Li, Y., Yoshino, H., Funayama, M., Ito, M., Iwamuro, H., Umemura, A., & Hattori, N. (2026). Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70411

Vancouver

Kamo H, Oyama G, Shimizu M, Takeshige-Amano H, Ogawa T, Sako W, et al. Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70411

BibTeX
@article{Kamo2026,
  author = {Kamo, Hikaru and Oyama, Genko and Shimizu, Mai and Takeshige-Amano, Haruka and Ogawa, Takashi and Sako, Wataru and Nishikawa, Noriko and Hatano, Taku and Li, Yuanzhe and Yoshino, Hiroyo and Funayama, Manabu and Ito, Masanobu and Iwamuro, Hirokazu and Umemura, Atsushi and Hattori, Nobutaka},
  title = {Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70411}
}
Kostenlos starten →